1.	Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: NABTT-0504 CDR0000495253, U01CA062475, ABTC-0504, NABTT-0504, NCT00379080
2.	Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2005-0717, P30CA016672, MDA-2005-0717, NCI-7409, CDR0000504104, 7409, NCT00390468
3.	Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CASE10805, U01CA062502, P30CA043703, 7401, NCT00408902
4.	Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 080101, 08-C-0101, NCI-08-C-0101, P07260, NCT00667394
5.	Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 01-301, NCT00064584
6.	MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C03001, NCT00274248